7 Quotes by Hamilton Moses

We've seen growth and a real doubling of funding in all sectors. The proportions are really unchanged over the decade, with roughly 60 percent coming from industry and the remainder coming from government and foundations.

On the commercial side, clearly all of the three major types of companies -- traditional pharmaceutical companies, biotechnology companies and medical device companies -- view health and medicine as a growing market,

If we're soon going to be spending $100 billion a year, we'd better have treatments that work over a long period of time against diseases that are important today and will be more important tomorrow. If we don't know those conditions are satisfied, we can't judge whether we're getting our money's worth,

There aren't a lot of diseases where we can point to and say we have an answer today that we didn't have a decade ago.

We were surprised that the increase has been as steady over the decade and as large as it has been.

It raises the question ... are we getting our money's worth? Are we capturing the full value of that significant investment?

For all sponsors, the challenge is patience. Biomedical research is an inherently high risk and lengthy process,